The litigators : a novel

The partners at Finley & Figg—all two of them—often refer to themselves as “a boutique law firm.” Boutique, as in chic, selective, and prosperous. They are, of course, none of these things. What they are is a two-bit operation always in search of their big break, ambulance chasers who’ve been in the trenches much too long making way too little. Their specialties, so to speak, are quickie divorces and DUIs, with the occasional jackpot of an actual car wreck thrown in. After twenty plus years together, Oscar Finley and Wally Figg bicker like an old married couple but somehow continue to scratch out a half-decent living from their seedy bungalow offices in southwest Chicago. And then change comes their way. More accurately, it stumbles in. David Zinc, a young but already burned-out attorney, walks away from his fast-track career at a fancy downtown firm, goes on a serious bender, and finds himself literally at the doorstep of our boutique firm. Once David sobers up and comes to grips with the fact that he’s suddenly unemployed, any job—even one with Finley & Figg—looks okay to him. With their new associate on board, F&F is ready to tackle a really big case, a case that could make the partners rich without requiring them to actually practice much law. An extremely popular drug, Krayoxx, the number one cholesterol reducer for the dangerously overweight, produced by Varrick Labs, a giant pharmaceutical company with annual sales of $25 billion, has recently come under fire after several patients taking it have suffered heart attacks. Wally smells money. A little online research confirms Wally’s suspicions—a huge plaintiffs’ firm in Florida is putting together a class action suit against Varrick. All Finley & Figg has to do is find a handful of people who have had heart attacks while taking Krayoxx, convince them to become clients, join the class action, and ride along to fame and fortune. With any luck, they won’t even have to enter a courtroom! It almost seems too good to be true. And it is.

The partners at Finley & Figg often refer to themselves as a 'boutique law firm.' Boutique, as in chic, selective, and prosperous. Oscar Finley and Wally Figg are none of these things. They are a two-bit operation of ambulance chasers who bicker like an old married couple. Until change comes their way-or, more accurately, stumbles in. After leaving a fast-track career and going on a serious bender, David Zinc is sober, unemployed, and desperate enough to take a job at Finley & Figg.
 
Now the firm is ready to tackle a case that could make the partners rich-without requiring them to actually practice much law. A class action suit has been brought against Varrick Labs, a pharmaceutical giant with annual sales of $25 billion, alleging that Krayoxx, its most popular drug, causes heart attacks. Wally smells money. All Finley & Figg has to do is find a handful of Krayoxx users to join the suit. It almost seems too good to be true . . . and it is.

Includes an excerpt of John Grisham’s Calico Joe and a special preview of his upcoming novel The Racketeer 

#1 NEW YORK TIMES BESTSELLER • After leaving a fast-track legal career and going on a serious bender, David Zinc is sober, unemployed, and desperate enough to take a job at Finley & Figg, a self-described “boutique law firm” that is anything but. Oscar Finley and Wally Figg are in fact just two ambulance chasers who bicker like an old married couple. But now the firm is ready to tackle a case that could make the partners rich—without requiring them to actually practice much law. A class action suit has been brought against Varrick Labs, a pharmaceutical giant with annual sales of $25 billion, alleging that Krayoxx, its most popular drug, causes heart attacks. Wally smells money. All Finley & Figg has to do is find a handful of Krayoxx users to join the suit. It almost seems too good to be true ... and it is. Don’t miss John Grisham’s new book, THE EXCHANGE: AFTER THE FIRM! Law firm partners Oscar Finley and Wally Figg see a chance for huge financial gain when they learn of a pending class action lawsuit against the makers of Krayoxx, a popular cholesterol-reducing drug suspected of causing heart attacks.